Brief: Nkarta Updates Clinical Progress Of CAR-NK Cell Therapy For Patients With Relapsed, Refractory Acute Myeloid Leukemia

Nkarta

27/06/2023 13:48

June 27 (Reuters) - Nkarta Inc  NKTX.O :
    * NKARTA UPDATES CLINICAL PROGRESS OF CAR-NK CELL THERAPY
NKX101
FOR PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA
    * NKARTA INC - NKX101 WAS WELL TOLERATED ACROSS DOSE-LEVELS
AND
LYMPHODEPLETION REGIMENS
    * NKARTA INC - 2 CRS WITH MRD NEGATIVITY
    * NKARTA INC - UPDATED CLINICAL DATA FROM NKX101 PROGRAM
EXPECTED
IN 1H 2024
    * NKARTA INC - NO DOSE-LIMITING TOXICITIES WERE OBSERVED
ACROSS
ALL COHORTS
    * NKARTA INC - SAFETY PROFILE OF NKX101 WAS CONSISTENT
ACROSS BOTH
LYMPHODEPLETION REGIMENS

Source text for Eikon:  ID:nGNX3pH6V9 
Further company coverage:  NKTX.O 

 ((reuters.briefs@thomsonreuters.com;))